Skip to main content
. Author manuscript; available in PMC: 2023 Sep 28.
Published in final edited form as: Alzheimers Dement. 2023 Feb 16;19(8):3389–3405. doi: 10.1002/alz.12960

Table 1.

Distribution of subjects in BU-ADRC Hippocampus data including clinical and neuropathological measurement

Distribution of subjects in BU Hippocampus data (n=207)
Variable AD_pure AD+VaD AD+LBD AD other Control
N 79 56 47 4 21
Age(yr) (SD) 76.9 (8.30) 84.6 (9.70) 79.9 (5.85) 80.3 (5.56) 89.0 (9.00)
Female N (%) 12 (15.19) 17 (30.36) 7 (14.89) 0 (0) 10 (47.62)
RIN
≤4.3 24 12 12 2 4
4.3<x≤5.6 18 19 14 1 1
5.6<x≤6.9 16 14 14 1 5
>6.9 21 11 7 0 11
CDR
0 0 0 1 9 0
0.5 1 0 2 3 0
1 1 1 5 2 0
2 1 3 11 0 0
3 30 16 30 3 0
Braak
1 0 0 0 0 4
2 0 0 0 0 11
3 1 3 2 0 5
4 3 5 5 3 0
5 26 21 17 1 1
6 49 27 23 0 0
CERAD
0 0 0 0 0 0
1 70 46 39 3 2
2 7 7 8 1 2
3 2 3 0 0 8
4 0 0 0 0 9

N: sample size; RIN: RNA integrity number; SD: standard deviation. Values for Age and RIN are expressed as Mean ± SD. AD other was defined as the AD patients not defined as pure AD, AD+VaD, or AD+LBD.